Clinical Trials
UCB clinical trials policy
UCB is committed to providing the opportunity to patients to make informed decisions about participating in clinical trials. UCB is committed to...
Clinical Trials
clinical trials are critical for determining the safety and efficacy of new medicines and are integral to Roche’s strategy of developing innovative medicines and...
Roche is committed to sharing data from clinical trials and has registered and posted summary reports for trials involving patients on clinicaltrials.gov and on roche-trials.com...
Clinical Trials
Disclosure Policy of the Astellas Group for Information on Conduct and Results of Clinical Trials.
The Astellas Group (*1) (hereinafter collectively “Astellas”) recognises that making clinical trial information and results more widely available to researchers, healthcare professionals, patients, and interested...
Clinical Trials
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO
Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Clinical Trials
CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial
CTI BioPharma Corp. announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive pre-NDA...
Clinical Trials
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Merck known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin...
Clinical Trials
Enox Biopharma, LTD. Announces First Enrollments of A Phase 1a/lb Clinical Trial
Enox Biopharma, Ltd., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections announced today the enrollment of the first subjects...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.